Ewing Sarcoma

P2, N=15, Completed, Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting --> Completed | N=30 --> 15

P1, N=30, Active, not recruiting, Cellectar Biosciences, Inc. | Trial primary completion date: Dec 2025 --> Aug 2026

The patient received six cycles of vincristine-doxorubicin-cyclophosphamide alternating with ifosfamide-etoposide, followed by partial amputation of the distal phalanx with clear margins. Ewing sarcoma of the great toe is exceptionally rare but can be successfully treated when identified early and managed with coordinated multimodal therapy. Clinicians should maintain vigilance for malignancy in non-healing digital lesions to ensure timely intervention and durable outcomes.

Multiple rare thyroid malignancies may present indistinguishably from ATC, emphasizing the need for meticulous histopathologic and molecular evaluation.

Intracranial EWS is exceptionally rare and poses a significant diagnostic challenge due to its nonspecific radiological features. Definitive diagnosis relies on integrated pathological and molecular genetic testing. This case underscores that a multimodal treatment strategy centered on maximal safe surgical resection, combined with radiotherapy and chemotherapy, can achieve favorable short-term oncological outcomes. A review of the literature highlights the prognostic importance of tumor location and extent of resection.

This review article focuses on four fusion-driven soft tissue tumors which illustrate different aspects of our evolving understanding of these tumors: (1) NUTM1-rearranged sarcoma, a prototypical example of a novel, clinically significant entity defined almost entirely by molecular genetics; (2) SRF-rearranged myoid neoplasm, an entity whose recognition greatly clarifies our understanding of pediatric "leiomyosarcomas;" (3) superficial FET-ETS neurocristic tumor, a very recently described, clinically benign entity sharing identical fusion events with often-lethal Ewing sarcoma; and (4) an evolving family of glomoid/myoid neoplasms harboring EWSR1::WT1 fusions, but clearly differing from desmoplastic small round cell tumor. These examples illustrate the complexity of fusion-driven soft tissue tumors and the importance of integrating molecular genetic testing with other clinicopathological data, rather than viewing it in isolation.

P=N/A, N=72, Recruiting, Mayo Clinic | Trial completion date: Aug 2028 --> Aug 2031

P2, N=85, Recruiting, Grupo Espanol de Investigacion en Sarcomas | Not yet recruiting --> Recruiting

The compensatory ATR signaling axis acts as a collateral dependency and therapeutic target in patient-derived xenograft models of multiple FET rearranged cancers. In summary, these findings describe how oncogenes can disrupt physiologic DNA repair and provide the preclinical rationale for testing ATR inhibitors in FET rearranged cancers as part of ongoing early phase clinical trials.

HMGA2 may be more readily implemented than ETV4 and DUX4, even in non-specialized hospitals. Thus, HMGA2 immunohistochemistry is a useful adjunct for CRS diagnosis. HMGA2 expression in CRS and other small round or epithelioid cell tumours should be tested in a larger series, particularly in non-DUX4 CRS and ATXN1/ATXN1L-rearranged sarcomas.

This mechanism was identified through a comprehensive expression analysis aimed at uncovering the drivers of cell cycle acceleration in Ewing sarcoma. The findings offer new insights into therapeutic strategies for this malignancy, which has seen little progress in treatment over several decades. This discovery holds the potential to transform the current landscape, as no effective molecularly targeted therapies have yet been developed.

We further compare EWSR1 with conventional antifibrotic approaches, outline research gaps, and propose directions for translational development. By positioning EWSR1 as a novel molecular node in fibrogenesis, this article underscores its promise as a next-generation therapeutic target for halting or reversing liver fibrosis.